|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Restructuring costs | |||||
| Impairment of long-lived assets | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other expenses, net: | |||||
| Share of losses from equity method investment | |||||
| Impairment of equity method investment | |||||
| Impairment of strategic investments | |||||
| Other income, net | |||||
| Total other expenses, net | |||||
| Income (loss) before provision for income taxes | |||||
| Provision for income taxes | |||||
| Net income (loss) attributable to common stockholders | |||||
| Net income (loss) per share attributable to common stockholders: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted-average shares used to compute net income (loss) per share attributable to common stockholders: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...